CytoMed Competitors

Stocks . USA . 
Stock . CytoMed Therapeutics Limited
GDTC Stock   0.93  0.01  1.06%   
CytoMed Therapeutics competes with Enlivex Therapeutics, MetaVia, NuCana PLC, Neurosense Therapeutics, and Lisata Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing CytoMed Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of CytoMed Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out CytoMed Therapeutics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of CytoMed Therapeutics competition on your existing holdings.
  
Build AI portfolio with CytoMed Stock
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CytoMed Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.050.976.73
Details
Intrinsic
Valuation
LowRealHigh
0.101.957.71
Details

CytoMed Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CytoMed Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CytoMed and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of CytoMed Therapeutics does not affect the price movement of the other competitor.

High positive correlations

CLGN
+ 0.82
NRSN
CLGN
+ 0.8
ENLV
PASG
+ 0.78
NRXS
NRSN
+ 0.77
ENLV
SONN
+ 0.76
XCUR
NCNA
+ 0.6
ENLV
  

High negative correlations

SONN
- 0.72
CLGN
PASG
- 0.69
CLGN
XCUR
- 0.66
CLGN
NRXS
- 0.59
CLGN
SONN
- 0.59
LSTA
SONN
- 0.59
NRSN

Risk-Adjusted Indicators

There is a big difference between CytoMed Stock performing well and CytoMed Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CytoMed Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ENLV  3.53 (0.28) 0.00 (0.05) 0.00 
 0.00 
 8.57 
(7.53)
 24.21 
MTVA  7.50 (1.21) 0.00  6.74  0.00 
 0.00 
 11.60 
(20.10)
 70.90 
NCNA  3.59 (0.71) 0.00 (0.44) 0.00 
 0.00 
 6.97 
(7.87)
 16.72 
NRSN  4.53 (0.20) 0.00 (0.11) 0.00 
 0.00 
 12.82 
(7.37)
 34.62 
LSTA  2.77 (0.22) 0.00 (0.10) 0.00 
 0.00 
 5.38 
(5.26)
 31.49 
CLGN  3.35 (0.61) 0.00 (0.73) 0.00 
 0.00 
 7.33 
(7.84)
 20.81 
NRXS  4.16  0.70  0.15  0.51  4.26 
(4.85)
 9.77 
(8.64)
 38.80 
PASG  5.86  0.65  0.16  0.21  6.07 
(6.30)
 14.59 
(9.29)
 58.13 
XCUR  5.81  1.15  0.10 (0.53) 7.57 
(6.92)
 21.22 
(9.76)
 63.80 
SONN  11.54 (1.53) 0.00 (3.31) 0.00 
 0.00 
 22.31 
(20.60)
 101.54 
All Fundamental Data

CytoMed Therapeutics Competitive Analysis

The better you understand CytoMed Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CytoMed Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CytoMed Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GDTC ENLV MTVA NCNA NRSN LSTA CLGN NRXS PASG XCUR
 1.06 
 0.93 
CytoMed
 4.12 
 0.93 
Enlivex
 39.11 
 3.30 
MetaVia
 0.30 
 3.34 
NuCana
 7.48 
 0.99 
Neurosense
 4.81 
 2.18 
Lisata
 5.99 
 1.57 
Collplant
 2.95 
 4.60 
Neuraxis
 5.80 
 14.28 
Passage
 1.18 
 6.00 
Exicure
Market Volatility
(90 Days Market Risk)
Dangerous
Risky
Somewhat reliable
Not too volatile
Very risky
Very risky
Unstable
Risky
Somewhat reliable
Dangerous
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Good
Good
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Small
Low
Strong
High
Low
Risky
Low
Strong
Strong
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Sell
Cautious Hold
Hold
Cautious Hold
Strong Sell
Current Ratio
N/A
15.44
N/A
5.83
15.09
22.33
16.21
N/A
9.23
1.26
Net Asset
7.37 M
27.69 M
16.26 M
14.77 M
4.58 M
35 M
18.71 M
4.76 M
102.41 M
15.06 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-2.24
N/A
N/A
EBITDA
(1.79 M)
(14.47 M)
(28.79 M)
(22.48 M)
(9.88 M)
(22.23 M)
(15.55 M)
(7.9 M)
(62.09 M)
(8.85 M)
Operating Margin
-4.52
N/A
N/A
N/A
N/A
-18.77
-45.55
-2.59
N/A
N/A
Current Valuation
9.18 M
211.93 M
3.69 M
(19.12 M)
29.07 M
(3.13 M)
15.73 M
48.52 M
19.75 M
34.46 M
Price To Book
1.99
13.12
2.83
0.42
12.82
1.08
2.29
22.98
1.55
5.56
Retained Earnings
(10.87 M)
(127.11 M)
(135.86 M)
(224.29 M)
(36.66 M)
(548.07 M)
(113.35 M)
(56.8 M)
(659.24 M)
(199.26 M)
Current Asset
N/A
6 M
N/A
47.66 M
N/A
N/A
17.03 M
N/A
144.91 M
N/A
Beta
-0.35
1.52
0.27
1.61
1.57
1.11
0.63
3.16
1.76
4.07
Number Of Employees
43
8
9
20
17
26
57
21
60
7
Shares Outstanding
11.73 M
237.38 M
2.31 M
1.91 M
29.55 M
8.82 M
12.78 M
9.99 M
3.18 M
6.37 M
Cash Flow From Operations
(1.69 M)
(13.01 M)
(24.71 M)
(19.12 M)
(10.13 M)
(19.36 M)
(14.09 M)
(6.1 M)
(47.96 M)
(2.91 M)
Total Debt
339.2 K
534 K
136 K
190 K
73 K
137 K
3.08 M
473.4 K
25.48 M
5.93 M
Return On Equity
-0.42
-0.58
-1.68
-1.82
-24.78
-0.72
-0.93
-30.71
-0.87
-2.18
Return On Asset
-0.23
-0.36
-0.58
-0.46
-3.04
-0.42
-0.42
-1.37
-0.32
-0.45
Number Of Shares Shorted
21.05 K
603.24 K
19.68 K
195.36 K
555.31 K
9.33 K
61.08 K
433.5 K
19.54 K
139.37 K
Book Value Per Share
0.62
0.72
2.88
8.39
-0.021
1.98
0.73
0.23
9.79
1.09
Current Liabilities
N/A
671.32 K
N/A
2.32 M
N/A
N/A
6.37 M
N/A
3.09 M
N/A
Total Asset
7.37 M
27.69 M
16.26 M
14.77 M
4.58 M
35 M
18.71 M
4.76 M
102.41 M
15.06 M
Short Ratio
0.1
0.71
0.08
3.38
1.15
0.33
1.6
0.47
0.41
0.07
Target Price
5.0
13.0
98.5
104.0
11.5
13.0
11.56
5.0
39.6
2.0
Debt To Equity
N/A
0.077
N/A
0.004
0.019
0.006
0.076
N/A
0.11
6.53
Shares Owned By Institutions
0.43
0.41
6.86
2.52
1.71
8.38
12.23
15.38
51.91
6.15
Market Capitalization
22.53 M
229.43 M
17.9 M
6.74 M
27.11 M
18.35 M
21.34 M
23.47 M
48.19 M
38.24 M
Price To Earning
N/A
-11.97
N/A
-7.52
N/A
N/A
92.6
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
-0.02
N/A
N/A
N/A
N/A
Price To Sales
15.03
N/A
N/A
N/A
N/A
17.15
8.62
15.59
N/A
74.42
Net Income
(1.84 M)
(15.01 M)
(27.59 M)
(19 M)
(10.21 M)
(19.98 M)
(16.61 M)
(8.24 M)
(64.77 M)
(9.7 M)
Earnings Per Share
-0.25
-0.54
-10.45
403.92
-0.36
-2.13
-1.03
-1.05
-14.62
-3.72
Shares Owned By Insiders
67.35
0.46
80.89
N/A
25.55
19.67
10.1
18.89
0.21
50.96
Revenue
52.01 K
N/A
N/A
N/A
N/A
1000 K
515 K
2.69 M
N/A
500 K
Working Capital
5.39 M
22.19 M
7.8 M
3.6 M
2.41 M
28.96 M
10.21 M
1.83 M
59.45 M
10.6 M
Cash And Equivalents
N/A
62.48 M
N/A
46.53 M
10.37 M
72.99 M
36.29 M
N/A
239.25 M
22.2 M
Cash Per Share
N/A
3.4
N/A
0.9
0.89
18.07
3.27
N/A
4.39
4.47
Gross Profit
675.25 K
N/A
N/A
N/A
N/A
1.07 M
1.56 M
2.84 M
N/A
(2.63 M)
Day Typical Price
0.93
0.96
3.53
3.33
0.98
2.17
1.61
4.64
14.89
6.05
Accumulation Distribution
1612.78
116496.0
540083.0
1708.9
31537.51
7121.68
320.56
2956.21
6459.06
0.0387
Market Facilitation Index
0.0
N/A
0.0
0.0
N/A
0.0
0.0
0.0
0.0
0.24
Daily Balance Of Power
(0.12)
(0.36)
(1.63)
0.1
(0.67)
0.4762
(0.77)
(0.78)
(0.48)
0.2917
Period Momentum Indicator
(0.01)
(0.04)
(2.12)
0.01
(0.08)
0.1
(0.10)
(0.14)
(0.88)
0.07
Rate Of Daily Change
0.99
0.96
0.61
1.0
0.93
1.05
0.94
0.97
0.94
1.01
Day Median Price
0.93
0.98
3.65
3.32
0.97
2.17
1.64
4.66
15.2
6.08
Price Action Indicator
(0.01)
(0.07)
(1.41)
0.025
(0.02)
0.065
(0.11)
(0.13)
(1.36)
(0.04)
Coefficient Of Variation
(447.99)
(5,717)
(913.15)
(815.36)
(6,506)
(4,303)
(842.10)
709.72
671.52
1005.0
Mean Deviation
3.8
3.53
7.5
3.59
4.53
2.77
3.35
4.16
5.86
5.81
Jensen Alpha
(1.47)
(0.28)
(1.21)
(0.71)
(0.20)
(0.22)
(0.61)
0.7024
0.649
1.15
Total Risk Alpha
(2.11)
(0.80)
(2.84)
(1.24)
(1.00)
(0.71)
(1.18)
(0.03)
0.0349
(0.44)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.1457
0.1634
0.1038
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
28.12
48.7
70.34
Standard Deviation
5.71
4.93
11.17
4.6
6.2
4.19
4.46
6.26
8.39
9.85
Kurtosis
4.29
0.7525
4.56
0.5939
1.45
7.12
0.4652
4.5
5.45
4.95
Potential Upside
6.03
8.57
11.6
6.97
12.82
5.38
7.33
9.77
14.59
21.22
Treynor Ratio
(0.71)
(0.05)
6.74
(0.44)
(0.11)
(0.1)
(0.73)
0.5107
0.2089
(0.53)
Maximum Drawdown
40.42
24.21
70.9
16.72
34.62
31.49
20.81
38.8
58.13
63.8
Variance
32.63
24.29
124.66
21.19
38.5
17.58
19.85
39.22
70.44
97.09
Market Risk Adjusted Performance
(0.70)
(0.04)
6.75
(0.43)
(0.1)
(0.09)
(0.72)
0.5207
0.2189
(0.52)
Risk Adjusted Performance
(0.15)
(0)
(0.07)
(0.08)
(0)
(0.01)
(0.07)
0.1066
0.1124
0.0783
Skewness
(0.57)
0.5257
(0.19)
(0.35)
0.7916
1.3
(0.13)
1.23
1.33
0.8102
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.26
6.07
7.57
Information Ratio
(0.24)
(0.04)
(0.12)
(0.15)
(0.03)
(0.05)
(0.14)
0.1234
0.1359
0.0884
Value At Risk
(9.33)
(7.53)
(20.10)
(7.87)
(7.37)
(5.26)
(7.84)
(8.64)
(9.29)
(9.76)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(4.85)
(6.30)
(6.92)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
5.3
6.98
8.39
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
18.19
36.81
57.32

CytoMed Therapeutics Competition Performance Charts

Five steps to successful analysis of CytoMed Therapeutics Competition

CytoMed Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by CytoMed Therapeutics in relation to its competition. CytoMed Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of CytoMed Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact CytoMed Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to CytoMed Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your CytoMed Therapeutics position

In addition to having CytoMed Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Russia On Wall Street Thematic Idea Now

Russia On Wall Street
Russia On Wall Street Theme
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 6 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
View All  Next Launch
When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:
How To Invest In CytoMed
Details
Is CytoMed Stock a good investment?
Details
What is CytoMed Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out CytoMed Therapeutics Correlation with its peers.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY